Whalesbook
### The Canadian Approval Setback
Onesource Specialty Pharma Ltd.'s stock experienced a steep decline, shedding as much as 18% on Tuesday, following the company's dismal third-quarter performance. The primary catalyst for the sell-off was a critical delay in the regulatory approval of its semaglutide formulation in Canada. This hurdle has directly impeded revenue streams and impacted profitability. The company serves as the manufacturing partner for Dr. Reddy's Laboratories' semaglutide, a drug facing regulatory scrutiny from Health Canada. This delay has prolonged the transition from manufacturing services agreements to commercial supply agreements, affecting revenue recognition.
### Financial Fallout and Margin Squeeze
The financial results for the quarter ended December 2025 reflected the severity of the situation. Consolidated revenue dropped 26% year-on-year to ₹290.34 crore. This revenue shortfall exacerbated operating leverage issues, while operating expenses rose 9% year-on-year to ₹273.018 crore. The impact of India's new Labour Code regulations also contributed to margin compression during the period. Consequently, Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) plummeted 88% year-on-year to ₹17.322 crore, with margins collapsing from 36.1% in the prior year quarter to a mere 6.0%. Net profit swung to a significant loss of ₹88.699 crore. As of January 27, 2026, the company's market capitalization hovered around ₹15,000-₹16,400 crore, with its stock trading near ₹1,300-₹1,430. The company's P/E ratio remains elevated, suggesting high market expectations or a challenging valuation given recent performance.
### Management's Long-Term View and GLP-1 Opportunity
Despite the subdued quarterly figures, management expressed confidence in underlying demand trends and long-term growth prospects. The order book is reportedly showing an upward trajectory, and interest in the biologics segment is increasing. Onesource has also onboarded another global biosimilar player, reinforcing its platform capabilities. Crucially, the company reaffirmed its fiscal year 2028 guidance, targeting ₹40,000 crore in organic revenue (potentially ₹50,000 crore with acquisitions) and maintaining a robust EBITDA margin target of 40% with a net debt to EBITDA ratio below 1.5x. A significant future growth driver highlighted is the anticipated global surge in demand for GLP-1 drugs like semaglutide, as patent protections expire in over 130 countries. The GLP-1 agonist market is projected for substantial growth, with estimates ranging from $48.84 billion by 2030 to over $170 billion by 2033, driven by obesity and diabetes treatment needs.
### Broader Market Context and Promoter Confidence
The Canadian market for semaglutide is nearing a critical juncture, with Novo Nordisk's patent protection expiring in January 2026, opening the door for generics. Dr. Reddy's faced a setback with a Notice of Non-Compliance from Health Canada, a move that has impacted its market entry timeline and, by extension, Onesource's revenue recognition. Other Indian players, such as Sun Pharma, might be better positioned for Canadian approvals according to some market analyses. Meanwhile, the Indian pharmaceutical sector generally is expected to report steady revenue growth in Q3 FY26, though profitability faces pressure from US generics competition and rising costs, including Labour Code implementation. A potentially positive development for the company was the reported reduction in promoter share pledging to 18.52% in the December 2025 quarter from 26.04% in the September 2025 quarter, a move often viewed as a sign of improved financial stability.